Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neuroone Medical Technologies (NMTC) EPS (Basic) (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of EPS (Basic) readings, the most recent being -$0.25 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 43.18% to -$0.25 in Q1 2026 year-over-year; TTM through Mar 2026 was -$0.35, a 40.68% increase, with the full-year FY2025 number at -$0.09, up 80.43% from a year prior.
  • EPS (Basic) hit -$0.25 in Q1 2026 for Neuroone Medical Technologies, down from -$0.03 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.06 in Q4 2024 to a low of -$0.44 in Q1 2025.
  • Median EPS (Basic) over the past 5 years was -$0.11 (2024), compared with a mean of -$0.13.
  • Biggest five-year swings in EPS (Basic): soared 142.86% in 2024 and later plummeted 300.0% in 2025.
  • Neuroone Medical Technologies' EPS (Basic) stood at -$0.11 in 2022, then dropped by 27.27% to -$0.14 in 2023, then skyrocketed by 142.86% to $0.06 in 2024, then plummeted by 150.0% to -$0.03 in 2025, then plummeted by 733.33% to -$0.25 in 2026.
  • The last three reported values for EPS (Basic) were -$0.25 (Q1 2026), -$0.03 (Q4 2025), and -$0.04 (Q3 2025) per Business Quant data.